Form D · Pharmaceuticals
Tellus Therapeutics, Inc.
Durham, NC · CIK 0001766205
Offering snapshot reported Feb 21, 2023 · SEC filing
- Reported sold
- $16M Offering amount: $35M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Nov 17, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Feb 21, 2023 | Initial | $15,999,999 | No comparison | 1 | SEC filing |
| Jul 16, 2021 | Initial | $2,000,000 | No comparison | Not reported | SEC filing |
| Jan 31, 2019 | Initial | $75,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-473928
Source: Form D, filed Feb 21, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Eric J. Benner | Director, Executive |
| Fred Callori | Director |
| Chris Garabedian | Director |
| Jason E. Karlic | Director, Executive |
| Jason E. Kralic | Director, Executive |
| Alex M. Ruckdaeschel | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
8 Davis Drive Suite 220
Durham, NC, 27709
Durham, NC, 27709